Thymosin Alpha-1 Research Peptide: A 28‑Amino‑Acid Immunomodulator for T‑Cell & Immune Signalling Studies

If your research investigates immunomodulation, T‑cell differentiation, or the molecular signalling pathways that govern immune responses, Thymosin Alpha-1 research peptide (Tα1) — also known as thymalfasin — offers a precisely defined and extensively studied synthetic tool. Tα1 is a highly conserved 28‑amino‑acid peptide that was first isolated from bovine thymus tissue and is the first biologically active peptide identified in the thymic preparation fraction 5.

It is a naturally occurring immunomodulatory polypeptide that has been the subject of decades of preclinical and clinical research, with regulatory approval in over 35 countries for the treatment of hepatitis B and C, and as an immune adjuvant in cancer therapy. Its synthetic form, thymalfasin, acts through Toll‑like receptors on myeloid and plasmacytoid dendritic cells, triggering a well‑defined signalling cascade that potentiates T‑cell mediated immune responses and restores immune homeostasis. This makes Thymosin Alpha-1 research peptide a valuable tool for laboratories investigating immunology, infectious disease, oncology, and immune restoration.

At Chinese Grey Peptides, we supply high‑purity Thymosin Alpha-1 research peptide to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is lyophilised, HPLC‑verified to >98% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into immune modulation, T‑cell biology, and therapeutic development begin with uncompromising quality.

What Is Thymosin Alpha‑1 and How Does It Work?

To fully appreciate the research potential of Thymosin Alpha-1 research peptide, it is essential to understand its biochemical structure, its mechanism of action, and its extensive clinical research history.

The 28‑Amino‑Acid Polypeptide

Thymosin Alpha‑1 is a synthetic 28‑amino‑acid polypeptide with the sequence Ac‑Ser‑Asp‑Ala‑Ala‑Val‑Asp‑Thr‑Ser‑Ser‑Glu‑Ile‑Thr‑Thr‑Lys‑Asp‑Leu‑Lys‑Glu‑Lys‑Lys‑Glu‑Val‑Val‑Glu‑Glu‑Ala‑Glu‑Asn‑OH (Ac‑SDAAVDTSSEITTKDLKEKKEVVEEAEN). Its molecular formula is C₁₂₉H₂₁₅N₃₃O₅₅, and its molecular weight is approximately 3108.28‑3108.32 g/mol. It has a CAS number of 62304‑98‑7 and is also known as thymalfasin and by the trade name Zadaxin.

Mechanism of Action: Toll‑Like Receptor Signalling and Immune Potentiation

The biological activity of Thymosin Alpha-1 research peptide is mediated through its interaction with Toll‑like receptors (TLRs) on dendritic cells, triggering a well‑defined signalling cascade:

• Toll‑Like Receptor Activation: Tα1 acts through Toll‑like receptors (TLRs) in both myeloid and plasmacytoid dendritic cells, leading to activation and stimulation of signalling pathways and initiation of production of immune‑related cytokines.

• MyD88‑Dependent Signalling: Upon binding to TLRs on dendritic cells, Tα1 initiates a signalling cascade predominantly mediated by the MyD88‑dependent pathway, a central signalling hub for most TLRs.

• TRAF6‑PKC‑NF‑κB Pathway: Tα1 activates a TRAF6‑atypical protein kinase C (PKC)‑IκB kinase signalling pathway that leads to the activation of nuclear factor‑κB (NF‑κB), which in turn initiates cytokine gene expression.

• T‑Cell Mediated Immune Potentiation: The primary mechanism involves potentiating T‑cell mediated immune responses by promoting the differentiation and maturation of T‑cells.

• Pleiotropic Immune Modulation: Tα1 has a pleiotropic mechanism of action, affecting multiple immune cell subsets involved in immune regulation, including T‑cells, NK‑cells, macrophages, and dendritic cells.

Research Note: Clinical History and Regulatory Status

Thymosin Alpha‑1 has been approved in over 35 countries for the treatment of hepatitis B and C, and as an immune stimulant and adjuvant. It is marketed as Zadaxin and has been used clinically since the 1990s. It has been studied in over 30 clinical trials involving more than 11,000 patients. However, it is not approved by the FDA for therapeutic use in the United States. In late 2023, the FDA moved Tα1 to Category 2, meaning pharmacists are not allowed to use it for compounding.

Key Research Applications for Thymosin Alpha‑1

Thymosin Alpha‑1 research peptide is a versatile tool with applications spanning several domains of biomedical research.

1. Immunology & T‑Cell Differentiation Research

As a peptide that potentiates T‑cell mediated immune responses, Tα1 is an essential tool for studying T‑cell biology and immune regulation. Research applications include:

• T‑Cell Maturation and Differentiation: Studying how Tα1 promotes the differentiation and maturation of T‑cells from hematopoietic stem cells.

• Dendritic Cell Activation: Investigating how Tα1 acts through Toll‑like receptors to activate dendritic cells and initiate cytokine production.

• NK‑Cell and Macrophage Modulation: Exploring how Tα1 affects NK‑cells and macrophages, key components of the innate immune system.

• Thymic Output Studies: Investigating how Tα1 enhances thymic output and restores immune function.

2. Infectious Disease & Viral Research

Tα1 has been extensively studied in models of viral infection and infectious disease:

• Hepatitis B and C: Tα1 has been shown to improve clinical outcomes in patients with HBV‑related acute‑on‑chronic liver failure by rebalancing the immune response — mitigating excessive inflammation and preventing immune paralysis.

• COVID‑19 Research: Tα1 has been used in the management of COVID‑19 to restore immune system homeostasis. A pilot trial has investigated thymalfasin for hospitalised patients with hypoxemia and lymphocytopenia due to COVID‑19 infection.

• Sepsis Models: The efficacy and safety of thymosin α1 for sepsis has been evaluated in a phase 3 trial (TESTS).

• Chronic Obstructive Pulmonary Disease: Clinical trials have confirmed that Tα1 can enhance immune function and suppress the inflammatory reaction in acute exacerbation of COPD.

3. Oncology & Immuno‑Oncology Research

Tα1 has been investigated in oncology research, particularly in the immuno‑oncology era:

• Non‑Small Cell Lung Cancer (NSCLC): Studies have shown that Tα1 can significantly improve overall survival in patients with surgically resectable NSCLC in the adjuvant setting.

• Liver Cancer: Tα1 has demonstrated improved overall survival in liver cancers in the adjuvant setting.

• Advanced Solid Tumours: The integration of Tα1 into the PRaG regimen (a personalised radioimmunotherapy approach) is a promising therapeutic strategy, offering enhanced efficacy.

• Chemotherapy Augmentation: Preclinical evidence suggests Tα1 may augment the efficacy of cancer chemotherapy by enhancing antitumor response.

• Stage IV Melanoma: Tα1 is in late‑stage clinical testing for stage IV melanoma in the United States and Europe.

4. Immune Restoration & Vaccine Adjuvant Research

Tα1 has been studied for its ability to restore immune function and enhance vaccine responses:

• Immune Restoration: Tα1 has been shown to restore immune function across multiple organ systems by stimulating new T‑cell production and reducing major inflammatory cytokines.

• Vaccine Adjuvant: Tα1 is being investigated as an enhancer of vaccine response in immune‑compromised populations, including older adults receiving booster doses of COVID‑19 vaccine.

• Long COVID Research: Tα1 is being studied as a potential treatment for Long COVID due to its immune‑boosting properties.

• Antioxidant and Neuroprotective Effects: Tα1 has demonstrated antioxidant properties, protecting brain tissue from oxidative damage.

5. Receptor Signalling & Cellular Signalling Research

Tα1 serves as a valuable tool for studying cellular signalling pathways:

• TLR Signalling Studies: Investigating the MyD88‑dependent signalling pathway and TRAF6‑PKC‑NF‑κB cascade.

• Galectin‑1 Interactions: Tα1 interacts with galectin‑1 at the molecular level, affecting carbohydrate binding and modifying its biological activity.

• Cytokine Gene Expression: Studying how Tα1 initiates cytokine gene expression in immune cells.

Chemical & Physical Specifications for Thymosin Alpha-1

Accurate characterisation of Thymosin Alpha‑1 research peptide is essential for reproducible experimental design.

Note: Thymosin Alpha‑1 is a 28‑amino‑acid acetylated polypeptide. It is typically supplied as a lyophilised powder. The peptide is for research use only (RUO). Not for human consumption. Thymosin Alpha‑1 is not FDA‑approved for therapeutic use in the United States.

Reconstitution & Handling Protocol for Thymosin Alpha-1

Proper reconstitution of Thymosin Alpha‑1 research peptide is critical for maintaining its structural integrity and biological activity. The peptide has a solubility of approximately 0.3 mg/mL in water.

Step 1 – Preparation

• Bring the sealed Thymosin Alpha-1 vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH 5‑7) to room temperature. Condensation can degrade the lyophilised powder.

• Clean your work surface with 70% ethanol and lay out sterile syringes, alcohol wipes and a clean work mat.

Step 2 – Vial Sanitisation

• Wipe the rubber stopper of the Thymosin Alpha‑1 vial with a fresh 70% ethanol wipe. Allow the alcohol to evaporate completely before piercing.

Step 3 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe. A common starting concentration for research applications is 1‑2 mg per 1 mL of diluent, yielding a 1‑2 mg/mL stock solution.

• Insert the needle and slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously, as shaking can cause denaturation.

Step 4 – Aliquoting & Storage

• Immediately after dissolution, aliquot the reconstituted Thymosin Alpha-1 into single‑use sterile vials.

• Store aliquots at –20°C. Avoid repeated freeze‑thaw cycles, as peptides are susceptible to degradation.

• Once thawed, store at 2‑8°C and use within a short period.

Concentration Reference Table for Thymosin Alpha-1

Adjust diluent volume based on your experimental requirements. For cell culture applications, typical working concentrations may range from 0.1‑10 µM.

Storage & Stability Guidelines for Thymosin Alpha-1

Why Choose Chinese Grey Peptides for Thymosin Alpha-1?

As an authentic licensed peptide supplier based in the USA, we supply Thymosin Alpha-1 research peptide and a wide range of research‑grade compounds under rigorous quality assurance protocols, fully aligned with Google’s E‑E‑A‑T standards (Experience, Expertise, Authoritativeness, Trustworthiness).

• Verified Purity: Independent HPLC analysis with purity guaranteed >98% for every batch.

• GMP‑Compliant Manufacturing: All peptides are synthesised under strict quality control conditions.

• Full Traceability: Batch‑specific Certificates of Analysis (COA) are available for every order.

• Wholesale Supply: We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics.

• USA‑Based Regulatory Compliance: All products are supplied strictly as research‑grade reagents for laboratory use only (RUO). Thymosin Alpha‑1 is not FDA‑approved for therapeutic use in the United States.

Researchers across the United States—including those at leading institutions—trust us for fast domestic delivery, transparent documentation and professional technical support.

FAQ: Thymosin Alpha‑1 Research Peptide

 What is Thymosin Alpha-1 research peptide?
Thymosin Alpha‑1 (thymalfasin) is a synthetic 28‑amino‑acid polypeptide that acts as a potent immunomodulator. It is the first biologically active peptide isolated from thymic tissue and has been studied for its ability to potentiate T‑cell mediated immune responses.

 What is the sequence and molecular weight of Thymosin Alpha-1?
The sequence is Ac‑Ser‑Asp‑Ala‑Ala‑Val‑Asp‑Thr‑Ser‑Ser‑Glu‑Ile‑Thr‑Thr‑Lys‑Asp‑Leu‑Lys‑Glu‑Lys‑Lys‑Glu‑Val‑Val‑Glu‑Glu‑Ala‑Glu‑Asn‑OH. Its molecular formula is C₁₂₉H₂₁₅N₃₃O₅₅, and its molecular weight is approximately 3108.28‑3108.32 g/mol.

What are the primary research applications for Thymosin Alpha-1?
Tα1 is used in immunology and T‑cell differentiation research, infectious disease and viral research (HBV, HCV, COVID‑19, sepsis), oncology and immuno‑oncology research (NSCLC, liver cancer, melanoma), immune restoration and vaccine adjuvant research, and receptor signalling and cellular signalling studies.

What is the mechanism of action of Thymosin Alpha-1?
Tα1 acts through Toll‑like receptors (TLRs) on dendritic cells via the MyD88‑dependent pathway, activating a TRAF6‑PKC‑NF‑κB signalling cascade that initiates cytokine gene expression and potentiates T‑cell mediated immune responses.

What clinical evidence supports Thymosin Alpha-1’s efficacy?
Tα1 has been approved in over 35 countries for hepatitis B and C and as an immune adjuvant. It has been shown to improve survival in HBV‑related acute‑on‑chronic liver failure and to improve overall survival in NSCLC and liver cancers. Over 30 clinical trials have been conducted involving more than 11,000 patients.

What purity does your Thymosin Alpha-1 meet?
Our Thymosin Alpha‑1 is tested to >98% purity by HPLC. A Certificate of Analysis (COA) is supplied with every order.

How should I reconstitute Thymosin Alpha-1?
Reconstitute with sterile bacteriostatic water or sterile PBS (pH 5‑7). Allow the vial to reach room temperature, then slowly inject the diluent against the inner glass wall and swirl gently. Do not shake.

How should I store reconstituted Thymosin Alpha-1?
Reconstituted Thymosin Alpha‑1 should be stored at 2‑8°C for short‑term use. For longer storage, aliquot immediately into single‑use vials and store at –20°C for up to 3 months. Avoid repeated freeze‑thaw cycles.

Thymosin Alpha-1 research peptide legal to purchase in the USA?
Yes. Thymosin Alpha‑1 is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United States for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims. Note: Thymosin Alpha‑1 is not FDA‑approved for therapeutic use in the United States.

 Does Chinese Grey Peptides ship internationally?
Yes. We ship across the UK, Europe (France, Germany, Spain, Sweden, Italy), and the USA from our US warehouse. Wholesale pricing is available for bulk orders.

1. Shop Page
2. Bulk Orders Page
3. Contact Page
4. Shipping & Return Page
5. Peptide Purity Page

• PubChem Thymalfasin / Thymosin Alpha-1
• FDA compounding risk information
• Google Product Structured Data
• Rank Math Product Schema / WooCommerce Product Schema

Ships to USA, Canada, UK & Europe

Chinese Grey Peptides supports shipping to the USA, Canada, the United Kingdom, France, Germany, Spain, Sweden, Italy, and Europe where permitted.

Shipping support may include:

• Order processing updates
• Packaging support
• Tracking information where available
• Wholesale shipment planning
• Destination-based shipping review
• Customer support during transit

Shipping times may vary by order size, carrier, destination, customs process, product status, and local requirements.

Why Choose Chinese Grey Peptides?

Chinese Grey Peptides focuses on quality, support, and clear communication. We help buyers review product details before placing an order.

Customers choose us for:

• Professional peptide supplier support
• Small and wholesale order options
• Product documentation support
• HPLC testing information where available
• Mass Spectrum documentation where available
• International shipping support
• Responsive communication
• Clear order assistance before payment

We aim to make the buying process transparent, professional, and documentation-focused.

Important Compliance Notice

Thymosin Alpha-1 may be regulated differently depending on the country, product type, labeling, intended use, and customer type. Chinese Grey Peptides does not provide medical advice, dosing instructions, injection guidance, immune-support claims, antiviral claims, anti-aging claims, disease claims, treatment claims, recovery claims, performance claims, or personal-use recommendations.

Customers are responsible for understanding and following all local laws, import rules, prescription requirements, compounding rules, and permitted-use requirements before ordering.

From its discovery as the first biologically active peptide isolated from thymic tissue to its well‑characterised role in potentiating T‑cell mediated immune responses through TLR signalling pathways, Thymosin Thymosin Alpha-1 peptide provides a precisely defined and extensively validated platform for advanced immunological research.

Its ability to activate dendritic cells via the MyD88‑dependent pathway, initiate TRAF6‑PKC‑NF‑κB signalling, and restore immune homeostasis—supported by decades of peer‑reviewed research, regulatory approval in over 35 countries, and clinical trials involving more than 11,000 patients—makes it a valuable addition to any laboratory investigating immunomodulation, T‑cell biology, infectious disease, or immuno‑oncology. By choosing high‑purity, lab‑verified Thymosin Alpha-1 research peptide from Chinese Grey Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your research with Thymosin Alpha-1? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s specific needs. Place your order now and receive GMP‑grade Thymosin Alpha‑1 delivered directly to your facility in the USA, UK, or Europe.